Literature DB >> 32092186

Implications of the Gut Microbiome in Parkinson's Disease.

Mohamed Elfil1, Serageldin Kamel1, Mohamed Kandil1, Brian B Koo1,2,3, Sara M Schaefer1.   

Abstract

Parkinson's disease is a common neurodegenerative disorder that presents with nonmotor and motor symptoms. The nonmotor manifestations of Parkinson's disease often begin years before the motor symptoms. Autopsy studies, including both Parkinson's disease patients and matched controls, demonstrated that α-synuclein aggregates in Parkinson's disease patients can be found in both the substantia nigra and the enteric nervous system. Therefore, it has been hypothesized that the pathological process that leads eventually to Parkinson's disease might initially take place in the enteric nervous system years before the appearance of motor features. The gut microbiome plays essential roles in the development and maintenance of different body systems. Dysbiosis of the normal gut microbiome is thought to be associated with pathophysiologic changes not only in the gastrointestinal system itself but also in the enteric and central nervous systems. These changes are thought to ultimately cause loss of dopaminergic neurons via various mechanisms including the release of neurotoxins into the systemic circulation, decreased production of neuroprotective factors, and triggering inflammatory and autoimmune responses. In this review, we review the gut microbiome changes in Parkinson's disease and discuss the mechanisms by which gut microbiome dysbiosis may be a contributing factor to the pathophysiology of Parkinson's disease.
© 2020 International Parkinson and Movement Disorder Society. © 2020 International Parkinson and Movement Disorder Society.

Entities:  

Keywords:  GM; PD; Parkinson's disease; gut microbiome; neuroinflammation; α-synuclein; α-synucleinopathy

Year:  2020        PMID: 32092186     DOI: 10.1002/mds.28004

Source DB:  PubMed          Journal:  Mov Disord        ISSN: 0885-3185            Impact factor:   10.338


  35 in total

1.  Slowing Parkinson's Disease Progression with Vaccination and Other Immunotherapies.

Authors:  Dhanya Vijayakumar; Joseph Jankovic
Journal:  CNS Drugs       Date:  2022-02-25       Impact factor: 5.749

Review 2.  Review of Metabolomics-Based Biomarker Research for Parkinson's Disease.

Authors:  Xin Li; Xiaoying Fan; Hongtian Yang; Yufeng Liu
Journal:  Mol Neurobiol       Date:  2021-11-26       Impact factor: 5.590

3.  Tungsten enzymes play a role in detoxifying food and antimicrobial aldehydes in the human gut microbiome.

Authors:  Gerrit J Schut; Michael P Thorgersen; Farris L Poole; Dominik K Haja; Saisuki Putumbaka; Michael W W Adams
Journal:  Proc Natl Acad Sci U S A       Date:  2021-10-26       Impact factor: 11.205

Review 4.  Gastrointestinal dysfunction in the synucleinopathies.

Authors:  Kathryn A Chung; Ronald F Pfeiffer
Journal:  Clin Auton Res       Date:  2020-11-27       Impact factor: 4.435

Review 5.  The Gut-Brain Axis: Two Ways Signaling in Parkinson's Disease.

Authors:  Nitu Dogra; Ruchi Jakhmola Mani; Deepshikha Pande Katare
Journal:  Cell Mol Neurobiol       Date:  2021-03-02       Impact factor: 5.046

6.  Oral Dysbiosis and Inflammation in Parkinson's Disease.

Authors:  Vanessa Fleury; Alkisti Zekeridou; Vladimir Lazarevic; Nadia Gaïa; Catherine Giannopoulou; Laurence Genton; José Cancela; Myriam Girard; Rachel Goldstein; Julien F Bally; Andrea Mombelli; Jacques Schrenzel; Pierre R Burkhard
Journal:  J Parkinsons Dis       Date:  2021       Impact factor: 5.568

Review 7.  Gut brain axis: an insight into microbiota role in Parkinson's disease.

Authors:  Sara Ayman Moustafa; Shrouk Mohamed; Abdelhameed Dawood; Jihan Azar; Ekramy Elmorsy; Noura A M Rizk; Mohamed Salama
Journal:  Metab Brain Dis       Date:  2021-08-09       Impact factor: 3.584

Review 8.  Consideration of Gut Microbiome in Murine Models of Diseases.

Authors:  Chunye Zhang; Craig L Franklin; Aaron C Ericsson
Journal:  Microorganisms       Date:  2021-05-14

Review 9.  The Combination of Tradition and Future: Data-Driven Natural-Product-Based Treatments for Parkinson's Disease.

Authors:  Zhijun Miao; Jinwei Bai; Li Shen; Rajeev K Singla
Journal:  Evid Based Complement Alternat Med       Date:  2021-07-14       Impact factor: 2.629

10.  The Add-On Effect of Lactobacillus plantarum PS128 in Patients With Parkinson's Disease: A Pilot Study.

Authors:  Chin-Song Lu; Hsiu-Chen Chang; Yi-Hsin Weng; Chiung-Chu Chen; Yi-Shan Kuo; Ying-Chieh Tsai
Journal:  Front Nutr       Date:  2021-06-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.